青蒿琥酯-苯芴醇联合阿莫地喹在无并发症恶性疟中的群体药代动力学
该研究基于两项随机对照试验(2015–2020年,非洲1国和东南亚2国)的數據,对青蒿琥酯-苯芴醇单用(n=443)或联用阿莫地喹(n=442)治疗无并发症恶性疟患者进行非线性混合效应模型分析,发现阿莫地喹对青蒿琥酯-苯芴醇的药代动力学无显著影响,药物相互作用预计很小。
要点
- 阿莫地喹对青蒿琥酯、双氢青蒿素和苯芴醇关键药代参数影响的几何均值比均落在0.80–1.25范围内。
- 联用阿莫地喹未显著改变青蒿琥酯-苯芴醇的药代动力学特征。
- 基于当前分析,青蒿琥酯-苯芴醇与阿莫地喹之间无临床相关药物相互作用。
核心结论
- 阿莫地喹对青蒿琥酯-苯芴醇药代动力学的影响预计很小。
- 基于当前分析,两药之间无临床相关药物相互作用,但需进一步大规模临床试验确认。
研究设计与样本
- 分析两项随机对照干预试验数据,2015–2020年在1个非洲国家和2个东南亚国家开展。
- 青蒿琥酯-苯芴醇单用组n=443,联用阿莫地喹组n=442,均为无并发症恶性疟患者。
- 两项研究均包含密集药代采样亚队列,其他患者为稀疏采样。
- 采用非线性混合效应模型分析青蒿琥酯、双氢青蒿素、苯芴醇、去丁基苯芴醇、阿莫地喹和去乙基阿莫地喹的浓度-时间数据。
主要发现
- 为所有药物建立的药代动力学模型显示良好的预测性能和拟合优度诊断。
- 阿莫地喹不是青蒿琥酯-苯芴醇药代动力学特征的显著协变量。
- 青蒿琥酯的Cmax和AUC(中位数[95%CI]):单用组256(159–407)ng/mL和2850(1820–4920)h·ng/mL,联用组230(123–391)ng/mL和2800(1570–4570)h·ng/mL。
- 双氢青蒿素的Cmax和AUC:单用组135(54.5–214)ng/mL和1870(813–3015)h·ng/mL,联用组116(40.8–186)ng/mL和1580(547–2680)h·ng/mL。
- 苯芴醇的Cmax和AUC:单用组15.2(2.90–31.3)μg/mL和600(275–1230)h·μg/mL,联用组14.1(2.72–31.4)μg/mL和586(269–1070)h·μg/mL。
临床怎么用
- 临床可认为青蒿琥酯-苯芴醇与阿莫地喹联用时无需因药物相互作用调整剂量。
局限性
- 需进一步大规模临床试验确认当前药物相互作用分析结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Resistance to the artemisinins and the artemisinin-based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin-based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar pharmacokinetic profiles, combined with an artemisinin derivative can help to delay or prevent artemisinin resistance and prolong the useful lifetime of the partner drugs. This study aims to characterize the pharmacokinetic properties of a recommended TACT, artemether-lumefantrine plus amodiaquine, using data from two large clinical trials. METHODS: We analysed data from two randomized, controlled intervention trials conducted between 2015 and 2020 in one African country and two Southeast Asian countries, in which artemether-lumefantrine was administered alone (n = 443) or together with amodiaquine (n = 442) to patients with uncomplicated P. falciparum malaria. Both studies included a sub-cohort with dense pharmacokinetic sampling, combined with sparse data in the other patients. Concentration-time data of artemether, dihydroartemisinin, lumefantrine, desbutyllumefantrine, amodiaquine and desethylamodiaquine were analysed using nonlinear mixed-effects modelling. RESULTS: Pharmacokinetic models were developed for all drugs and demonstrated good predictive performance and goodness-of-fit diagnostics. Coadministered amodiaquine was not a significant covariate on pharmacokinetic properties of artemether-lumefantrine. Model-predicted Cmax and AUC (median [95% confidence interval, CI]) for artemether were 256 (159-407) ng/mL and 2850 (1820-4920) h·ng/mL for artemether-lumefantrine alone, and 230 (123-391) ng/mL and 2800 (1570-4570) h·ng/mL for artemether-lumefantrine-amodiaquine. For dihydroartemisinin, values were 135 (54.5-214) ng/mL and 1870 (813-3015) h·ng/mL for artemether-lumefantrine alone, and 116 (40.8-186) ng/mL and 1580 (547-2680) h·ng/mL for artemether-lumefantrine-amodiaquine. For lumefantrine, values were 15.2 (2.90-31.3) μg/mL and 600 (275-1230) h·μg/mL for artemether-lumefantrine alone, and 14.1 (2.72-31.4) μg/mL and 586 (269-1070) h·μg/mL for artemether-lumefantrine-amodiaquine. Day 7 concentrations of lumefantrine were 452 (215-1240) and 438 (204-1030) μg/mL for artemether-lumefantrine alone and artemether-lumefantrine-amodiaquine, respectively. All geometric mean ratios (GMRs) for the drug-drug interaction (DDI) effect on key pharmacokinetic parameters of artemether, dihydroartemisinin and lumefantrine fell within the 0.80-1.25 range, with the majority of the corresponding 90% CI also contained within this range. This indicates no clinically relevant DDIs between artemether-lumefantrine and amodiaquine. CONCLUSIONS: The DDI effect of amodiaquine on the pharmacokinetics of artemether-lumefantrine is expected to be minimal, the based on the current analysis. However, further large-scale clinical trials are needed to confirm this finding.
引用
- Ding J, Hoglund RM, van der Pluijm RW, et al. Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. Br J Clin Pharmacol. 2025. PMID: 41052792. doi:10.1002/bcp.70301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。